Lorant Gonczi1, Zsuzsanna Vegh1, Petra Anna Golovics1, Mariann Rutka2, Krisztina Barbara Gecse1, Renata Bor2, Klaudia Farkas2, Tamás Szamosi3, László Bene4, Beáta Gasztonyi5, Tünde Kristóf6, László Lakatos7, Pál Miheller8, Károly Palatka9, Mária Papp9, Árpád Patai10, Ágnes Salamon11, Gábor Tamás Tóth12, Áron Vincze13, Edina Biro14, Barbara Dorottya Lovasz1, Zsuzsanna Kurti1, Zoltan Szepes2, Tamás Molnár2, Péter L Lakatos1. 1. First Department of Internal Medicine, Semmelweis University, Budapest, Hungary. 2. First Department of Medicine, University of Szeged, Szeged, Hungary. 3. Military Hospital - State Health Centre, Budapest, Hungary. 4. First Department of Medicine, Peterfy Hospital, Budapest, Hungary. 5. Second Department of Medicine, Zala County Hospital, Zalaegerszeg, Hungary. 6. Second Department of Medicine, B-A-Z County and University Teaching Hospital, Miskolc, Hungary. 7. Department of Internal Medicine, Csolnoky Ferenc Regional Hospital, Veszprém, Hungary. 8. Second Department of Internal Medicine, Semmelweis University, Budapest, Hungary. 9. Institute of Medicine, Department of Gastroenterology, University of Debrecen, Clinical Center, Debrecen, Hungary. 10. Department of Medicine and Gastroenterology, Markusovszky Hospital, Szombathely, Hungary. 11. Department of Gastroenterology, Tolna County Teaching Hospital, Szekszárd, Hungary. 12. Department of Gastroenterology, Janos Hospital, Budapest, Hungary. 13. First Department of Medicine, University of Pécs, Pécs, Hungary. 14. Department of Laboratory Medicine, Semmelweis University, Budapest, Hungary.
Abstract
BACKGROUND AND AIMS: Biosimilar infliximab CT-P13 received European Medicines Agency [EMA] approval in June 2013 for all indications of the originator product. In the present study, we aimed to evaluate the predictors of short- and medium-term clinical outcome in patients treated with the biosimilar infliximab at the participating inflammatory bowel disease [IBD] centres in Hungary. METHODS: Demographic data were collected and a harmonised monitoring strategy was applied. Clinical and biochemical activities were evaluated at Weeks 14, 30, and 54. Trough level [TL] and anti-drug antibody [ADA] concentrations were measured by enzyme-linked immunosorbent assay [ELISA] [LT-005, Theradiag, France] at baseline at 14, 30 and 54 weeks and in two centres at Weeks 2 and 6. RESULTS: A total of 291 consecutive IBD patients (184 Crohn's disease [CD] and 107 ulcerative colitis [UC]) were included. In UC, TLs at Week 2 predicted both clinical response and remission at Weeks 14 and 30 (clinical response/remission at Week 14: area under the curve [AUC] = 0.81, p < 0.001, cut-off: 11.5 μg/ml/AUC = 0.79, p < 0.001, cut-off: 15.3μg/ml; clinical response/remission at Week 30: AUC = 0.79, p = 0.002, cut-off: 11.5 μg/ml/AUC = 0.74, p = 0.006, cut-off: 14.5 μg/ml), whereas ADA positivity at Week 14 was inversely associated with clinical response at Week 30 [58.3% vs 84.8% ,p = 0.04]. Previous anti-tumour necrosis factor [TNF] exposure was inversely associated with short-term clinical remission [Week 2: 18.8% vs 47.8%, p = 0.03, at Week 6: 38.9% vs 69.7%, p = 0.013, at Week 14: 37.5% vs 2.5%, p = 0.06]. In CD, TLs at Week 2 predicted short-term [Week 14 response/remission, AUCTLweek2 = 0.715-0.721, p = 0.05/0.005] but not medium-term clinical efficacy. In addition, early ADA status by Week 14 [p = 0.04-0.05 for Weeks 14 and 30], early clinical response [p < 0.001 for Weeks 30/54] and normal C-reactive protein [CRP] at Week 14 [p = 0.005-0.0001] and previous anti-TNF exposure [p = 0.03-0.0001 for Weeks 14, 30, and 54] were associated with short-and medium-term clinical response and remission. CONCLUSIONS: In UC, early TLs were predictive for short- and medium-term clinical efficacy, whereas in CD, Week 2 TLs were associated only with short-term clinical outcomes.
BACKGROUND AND AIMS: Biosimilar infliximab CT-P13 received European Medicines Agency [EMA] approval in June 2013 for all indications of the originator product. In the present study, we aimed to evaluate the predictors of short- and medium-term clinical outcome in patients treated with the biosimilar infliximab at the participating inflammatory bowel disease [IBD] centres in Hungary. METHODS: Demographic data were collected and a harmonised monitoring strategy was applied. Clinical and biochemical activities were evaluated at Weeks 14, 30, and 54. Trough level [TL] and anti-drug antibody [ADA] concentrations were measured by enzyme-linked immunosorbent assay [ELISA] [LT-005, Theradiag, France] at baseline at 14, 30 and 54 weeks and in two centres at Weeks 2 and 6. RESULTS: A total of 291 consecutive IBD patients (184 Crohn's disease [CD] and 107 ulcerative colitis [UC]) were included. In UC, TLs at Week 2 predicted both clinical response and remission at Weeks 14 and 30 (clinical response/remission at Week 14: area under the curve [AUC] = 0.81, p < 0.001, cut-off: 11.5 μg/ml/AUC = 0.79, p < 0.001, cut-off: 15.3μg/ml; clinical response/remission at Week 30: AUC = 0.79, p = 0.002, cut-off: 11.5 μg/ml/AUC = 0.74, p = 0.006, cut-off: 14.5 μg/ml), whereas ADA positivity at Week 14 was inversely associated with clinical response at Week 30 [58.3% vs 84.8% ,p = 0.04]. Previous anti-tumour necrosis factor [TNF] exposure was inversely associated with short-term clinical remission [Week 2: 18.8% vs 47.8%, p = 0.03, at Week 6: 38.9% vs 69.7%, p = 0.013, at Week 14: 37.5% vs 2.5%, p = 0.06]. In CD, TLs at Week 2 predicted short-term [Week 14 response/remission, AUCTLweek2 = 0.715-0.721, p = 0.05/0.005] but not medium-term clinical efficacy. In addition, early ADA status by Week 14 [p = 0.04-0.05 for Weeks 14 and 30], early clinical response [p < 0.001 for Weeks 30/54] and normal C-reactive protein [CRP] at Week 14 [p = 0.005-0.0001] and previous anti-TNF exposure [p = 0.03-0.0001 for Weeks 14, 30, and 54] were associated with short-and medium-term clinical response and remission. CONCLUSIONS: In UC, early TLs were predictive for short- and medium-term clinical efficacy, whereas in CD, Week 2 TLs were associated only with short-term clinical outcomes.
Authors: Konstantinos Papamichael; Adam S Cheifetz; Gil Y Melmed; Peter M Irving; Niels Vande Casteele; Patricia L Kozuch; Laura E Raffals; Leonard Baidoo; Brian Bressler; Shane M Devlin; Jennifer Jones; Gilaad G Kaplan; Miles P Sparrow; Fernando S Velayos; Thomas Ullman; Corey A Siegel Journal: Clin Gastroenterol Hepatol Date: 2019-03-27 Impact factor: 11.382
Authors: Rebecca Sagar; Marco V Lenti; Tanya Clark; Helen J Rafferty; David J Gracie; Alexander C Ford; Anthony O'Connor; Tariq Ahmad; P John Hamlin; Christian P Selinger Journal: Inflamm Intest Dis Date: 2021-04-13
Authors: Che-Yung Chao; Alex Al Khoury; Achuthan Aruljothy; Sophie Restellini; Jonathan Wyse; Waqqas Afif; Alain Bitton; Peter L Lakatos; Talat Bessissow Journal: Dig Dis Sci Date: 2018-11-16 Impact factor: 3.199
Authors: Lorant Gonczi; Zsuzsanna Kurti; Mariann Rutka; Zsuzsanna Vegh; Klaudia Farkas; Barbara D Lovasz; Petra A Golovics; Krisztina B Gecse; Balazs Szalay; Tamas Molnar; Peter L Lakatos Journal: BMC Gastroenterol Date: 2017-08-08 Impact factor: 3.067